For the millions of people managing type 2 diabetes who find weekly injections burdensome, a longer-acting GLP-1 receptor agonist administered just once every two weeks could represent a meaningful quality-of-life advance — provided it delivers equivalent or superior glycemic control. This trial suggests it does, and then some.
Across 272 Chinese adults with type 2 diabetes (mean HbA1c 8.35%, mean BMI 27.9 kg/m²) randomized across five arms, bofanglutide at its optimal doses demonstrated numerically greater HbA1c reductions than semaglutide 1 mg weekly at 24 weeks. The biweekly 18 mg dose achieved a mean HbA1c reduction of approximately 2.28 percentage points from baseline, versus 1.60 points for semaglutide — a treatment difference of roughly 0.68 percentage points favoring bofanglutide. The weekly 24 mg bofanglutide arm performed similarly, achieving about 2.32 points of reduction. Secondary endpoints and safety data were also assessed, though full safety details were truncated in the available excerpt.
Contextually, bofanglutide joins an increasingly competitive extended-dosing GLP-1 landscape. Tirzepatide's dual GIP/GLP-1 mechanism has already reset efficacy expectations, and once-monthly agents are under investigation elsewhere. What distinguishes this trial is the biweekly dosing interval, which — if confirmed in phase 3 — could improve adherence in real-world settings where injection fatigue is a documented barrier. However, important limitations temper enthusiasm: this is a phase 2b trial with a modest sample size, conducted exclusively in a Chinese population with relatively modest BMI, limiting generalizability to Western or more obese cohorts. The open-label design also introduces performance bias risk. Head-to-head comparisons used semaglutide 1 mg, not the higher 2 mg dose now widely used. Overall, this finding is promising and incrementally significant, but replication in larger, more diverse phase 3 trials is essential before clinical positioning can be established.